Press Releases
CAESAREA, Israel, February 4, 2015 – Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, today announced that Sandra Adzic has been named Vice President of International Sales, effective immediately. In her new position, Ms. Adzic will be responsible for creating and implementing sales strategy in Asia and Europe that will contribute to the Company’s overall growth plan. Ms. Adzic will report directly to Ori Hadomi, Mazor’s Chief Executive Officer.
Previously, Ms. Adzic was Senior Area Sales Manager, where she contributed to the Company’s growth in the Asian markets. Prior to joining Mazor in 2011, she held several managerial positions in sales including positions at Mennen Medical ltd and Caesarea Medical Electronics. Ms. Adzic replaces Avi Posen, who will stay with the Company until March 31, 2015 to ensure a seamless transition.
“We are very pleased to announce that Sandra has been named Mazor’s Vice President of International Sales and we are confident that she will be successful in the position. Ms. Adzic is a seasoned sales executive with extensive experience in leading distribution channels and has had success at each level, including most recently heading up our sales effort in the APAC region,” commented Mr. Hadomi. “We believe that the Company has a significant opportunity to build brand awareness for the Renaissance system and Sandra will play an integral role in advancing our international growth strategy in Asia and Europe.”
Mr. Hadomi added, “I also want to thank Avi for his significant contribution to the growth and success of Mazor over the years and we wish him success in his new endeavors.”
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
David Schemelia – Media
646.201.5431
Latest Tweet
Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf… https://t.co/LJDbcI17O1